Jon Moore
Chief Scientific Officer, Head of Translational Sc
biochemistry
Horizon Discovery
Austria
Biography
Jon Moore joined Horizon Discovery to manage its portfolio of target validation alliances in 2012 and became CSO in 2014. As Head of Translational Science he leads a broad ranging internal research program that aims to deliver opportunities for spin out companies and also milestoned licensing deals. Initially, this focused on synthetic lethal and immuno-oncology approaches to cancer, but is now widening its scope to encompass cell therapies. Jon is a Director and co-founder of Avvinity Therapeutics, a joint venture between Horizon and Centauri Therapeutics that is exploring the potential of a novel ablative therapy for cancer. Prior to joining Horizon, Jon spent 10 years in drug discovery at Vernalis rising to Head of Biology. Here he led various internal research programs and also the research alliance in cancer metabolism with GlaxoSmithKline. Before moving to industry, Jon gained extensive postdoctoral research experience in the field of cell cycle control in the laboratories of Sally Kornbluth and thenNobel Prize winner, Tim Hunt, publishing a landmark Science paper judged one of the best in the field in 2003. Jon holds a PhD from the University of Newcastle upon Tyne, is a Fellow of the Royal Society of Biology and is author of more than 35 peer reviewed papers.
Research Interest
biochemistry, cancer, immunology
